Immune Design

^{Priced, Nasdaq: IMDZ}

Early-stage biotech developing immunotherapy oncology treatments.

Industry: Health Care

First Day Return: +0.4%

IMDZ

Early-stage biotech developing immunotherapy oncology treatments.

IPO News for Immune Design

Cancer biotech Bellicum Pharmaceuticals files for a $115 million IPO 11/18/14
The next big cancer biotech: Juno Therapeutics files for a $150 million IPO 11/17/14
US IPO Pricing Recap: The crazy chicken flies while 8 IPOs trade down or flat 07/25/14

IPO Data
IPO Date	07/23/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$60
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.immunedesign.com
Headquarters	Seattle, WA, United States
Founded	2008
Employees at IPO	24

IPO News for Immune Design

Immune Design (IMDZ) Performance